R. E. Mitchell / Bioorg. Med. Chem. Lett. 20 (2010) 1910–1912
1911
Table 1
HPLC characteristics of stereomersa
N
Stereomer
Elution times (min)
Iminopyrrolidine 5
(CH2)n
H
(CH2)n
H
(CH2)n
H
i, ii
iii
Lactam 4
O
O
t
t
N
N
O
CO2 Bu
CO2 Bu
N
CO2H
4.97
5.23
4.29
4.54
L,
L- and
D
L
,D
-
-
C-OtBu
C-OtBu
H
D,L
- and
,D
O
O
a
HPLC used an ODS Hypersil C18 column, 250 Â 0.4 mm, flow rate 0.8 ml minÀ1
,
and isocratic elution with solvent compositions of CH3CN/H2O/MeOH + 0.05% TFA,
70:25:5 for 4, 50:45:5 for 5.
(CH2)n
H
(CH2)n
v
iv
H
Table 2
O
O
N
t
N
Antibacterial activitya of iminopyrrolidine stereomers
CO2H
CO2 Bu
H
C-OtBu
Stereomer
Zone size (mm) at loading of
O
3A, n=1
3B, n=2
0.1
l
g
1.0
l
g
10
lg
100 lg
10
—
19
6
L
,
,
L-
A: n=1
B: n=2
10
—
19
10
—
L
D-
D
,L
-
Scheme 1. Reagents and conditions: (i) tBuOAc, HClO4; (ii) (tBuO)2CO, DMAP,
MeCN, 0 °C; (iii) HC[N(CH3)2]3, CH3OCH2CH2OCH3, 72 °C, 88%; (iv)
[(CH3)2CHCH2]2AlH, THF, À78 °C, 61%; (v) TFA/CH2Cl2, 10 M, 72%.
D
,D-
—
a
Agar diffusion assay, samples applied in 10 lL water to 4 mm diameter wells.
strong inhibition at 1
natural product. In contrast, the
at loadings up to 100
g (i.e., >104 less active). The
reomers showed intermediate degrees of inhibition:
loading was comparable to - at 0.1 g, and - at 100
comparable to - at 0.1 g. The estimated differentials in concen-
trations for -: -: -: - to give comparable inhibitions there-
fore are 1: 102: 103: >104. The activity observed for the
stereomer was concluded to be real rather than from the presence
of a low concentration of -stereomer. HPLC analysis of -stere-
omer spiked with ca. 1% of the -product clearly showed this as a
resolved ‘pimple’ not present in the parent, indicating that the
stereomer did not contain the -stereomer. If there were a pres-
ence of -stereomer at a concentration below HPLC detectability
this would be significantly below the concentration to account
for the activity observed for the -stereomer.
The natural product 2-imino-3-methylene-5-
valyl)pyrrolidine was found to contain an -valine and was pro-
posed to have the -stereochemistry at the 5-position of the imino-
pyrrolidine ring.1 In the present study, the HPLC characteristics of
synthetic -stereomer were the same as those of the natural prod-
uct, and differed from the
l
g (19 mm zone), comparable to that of the
-stereomer gave no inhibition
- and -ste-
- at a 10
g was
The same methodology outlined was also used to prepare sev-
eral additional 2-imino-3-methylene-5- -carboxy? -amino acid
D
,D
L
L
l
L,
D
D
,L
conjugates for comparative antibacterial testing. Each was purified
to homogeneity, as evaluated by HPLC, and their identity con-
firmed by MS. The amino acid component of these included gly-
cine, alanine, b-alanine, 2-methyl alanine, leucine, phenylalanine,
proline, and the dipeptide valylleucine. These products generally
displayed an antibacterial activity similar to that of the threonine-
and valine-containing natural products, although some (b-alanine,
glycine, val-leu) were active to a lesser degree (2.5-, 5-, 20-fold,
respectively).
L,
D
lg
L
,L
l
D,L
l
L
,
L
L
l
D,D
L
,L
,
D
D
,L
L,D-
L
,L
L,D
L,L
L,D
-
Synthesis of the six-membered ring homologs started with 2-
L,L
oxopiperidine-6-
tained from the cyclisation of 2-L
L
-carboxylic acid (Scheme 1B), which was ob-
L
,
L
-aminoadipic acid.6 Introduction
of the exocyclic methylene lead to 3B, 3-methylenepiperidine-6-
carboxylic acid (Scheme 1B). This was then coupled with various
amino acids (as their methyl ester) followed by conversion of the
lactam carbonyl to the 2-imino functionality, and base hydrolysis
to the free carboxylic acid (Scheme 2B). Three amino acid-coupled
L,D
L
(carboxy-L-
L
L
products were prepared (L-Val, L-Ile, L-Thr); in all cases only low
L
,L
overall yields were achieved, but sufficient material was obtained
for characterisation (HPLC data and FAB-MS, and for the Val conju-
gate, full NMR analysis) and antibacterial testing. Each of the com-
D,L-stereomer, and therefore the natural
product is confirmed to be the
L,L
-stereomer.1
(CH2)n
H
(CH2)n
i
ii
H
3
O
H3CO
N
N
N
H
CO2CH3
H
C
O
N
H
CO2CH3
H
C
O
H
4
(CH2)n
H
(CH2)n
H
iii
iv
HN
N
HN
N
N
H
CO2H
H
C
O
N
CO2CH3
H
C
O
H
H
H
5A, n=1
5B, n=2
A: n=1
B: n=2
Scheme 2. Reagents and conditions: (i) DCCD, MeCN, then ValOMe(base), 75%; (ii) Me3O+BF4À, CH2Cl2 2 h, product used without purification; (iii) NH4Cl, MeOH, 70 °C 16 h,
19% from i; (iv) aq 0.1 M NaOH, 62%.